IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Song HU, et al.

Art Unit: 1652

Serial No.: 09/903,582

Examiner: Delia M. RAMIREZ

Filed: July 13, 2001

Atty. Docket: CL001274

For: ISOLATED HUMAN SECRETED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN SECRETED

PROTEINS, AND USES THEREOF

Statement Regarding Duty to Disclose Information Material To Patentability Under 37 CFR 1.56 (a) and (b)

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Madame:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this IDS Submission. However, the Office is authorized to charge any other necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: August 26, 2005

Celera Genomics 45 West Gude Drive, C1-1#316 Rockville, MD 20850

Tel: 240-453-3628 Fax: 240-453-3084 Justin D. Karjala, Reg No. 43,704

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 09/903,582 **Application Number** INFORMATION DISCLOSURE July 13, 2001 Filing Date STATEMENT BY APPLICANT Song HU et al. **First Named Inventor** 1646 Group Art Unit Delia M. RAMIREZ (use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet of CL001274

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner İnitials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s). mublisher city and/or country where published.	
20 7.17		Results of BLAST search of SEQ ID NO: 2 against Derwent (FastAlert and GeneSeqP) and NCBI (pataa) protein patent databases on December 8, 2003.	
n gada sebesé Santa sebesé Santa sebesé sebesé		SHIBANUMA M., et al.; "Cloning from a Mouse Osteoblastic Cell Line of a Set of Transforming-Growth-Factor-Beta1-Regulated Genes, One of which seems to Encode a Follistatin-Related Polypeptide"; European Journal of Biochemistry, Berlin, DE, vol. 217, no. 1, October 1993 (1993-10), pages 13-19, XP000857806; ISSN: 0014-2956	
مانداند و مداند مانداند و ماند و ماند و ماند و ماند و ماند		NIIMI TOMOAKI et al.; "A Drosophila Gene Encoding Multiple Splice Variants of Kazal-Type Serine Protease Inhibitor-Like Proteins with Potential Destinations of Mitochondria, Cytosol and the Secretory Pathway"; European Journal of Biochemistry, vol. 266, no. 1, November 1999 (1999-11), pages 282-292, XP002328519; ISSN: 0014-2956	
e government de la company de	de .	Copy of Supplementary Partial European Search Report dated May 19, 2005	
4	ery especial A		
क्षक १ ११५ व		No no space of comparison and comparison of the contract of	ļ.,
sterik mile		No proceed that modification of an advance of the control of the	ļ

_		والحيوا ورهورا ووالموالين والإنجاز والمحاصر المالي المالية المحاد المالية	<u> </u>		
, —				The second secon	
	Examiner			Date	
	Signature			Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.